Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV

Kumari G. Lokugamage, Naoko Yoshikawa-Iwata, Naoto Ito, Douglas M. Watts, Philip R. Wyde, Nan Wang, Patrick Newman, Chien-Te Tseng, C. J. Peters, Shinji Makino

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

We tested the efficacy of coronavirus-like particles (VLPs) for protecting mice against severe acute respiratory syndrome coronavirus (SCoV) infection. Coexpression of SCoV S protein and E, M and N proteins of mouse hepatitis virus in 293T or CHO cells resulted in the efficient production of chimeric VLPs carrying SCoV S protein. Balb/c mice inoculated with a mixture of chimeric VLPs and alum twice at an interval of four weeks were protected from SCoV challenge, as indicated by the absence of infectious virus in the lungs. The same groups of mice had high levels of SCoV-specific neutralizing antibodies, while mice in the negative control groups, which were not immunized with chimeric VLPs, failed to manifest neutralizing antibodies, suggesting that SCoV-specific neutralizing antibodies are important for the suppression of viral replication within the lungs. Despite some differences in the cellular composition of inflammatory infiltrates, we did not observe any overt lung pathology in the chimeric-VLP-treated mice, when compared to the negative control mice. Our results show that chimeric VLP can be an effective vaccine strategy against SCoV infection.

Original languageEnglish (US)
Pages (from-to)797-808
Number of pages12
JournalVaccine
Volume26
Issue number6
DOIs
StatePublished - Feb 6 2008

Fingerprint

Coronavirus
Coronavirinae
mice
Neutralizing Antibodies
Coronavirus Infections
neutralizing antibodies
proteins
lungs
Lung
Murine hepatitis virus
Severe Acute Respiratory Syndrome
CHO Cells
HEK293 Cells
Protein S
alum
virus replication
S protein, severe acute respiratory syndrome coronavirus
Severe acute respiratory syndrome coronavirus
infection
Vaccines

Keywords

  • Mouse
  • Neutralizing antibody
  • SARS coronavirus
  • Virus-like particles

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. / Lokugamage, Kumari G.; Yoshikawa-Iwata, Naoko; Ito, Naoto; Watts, Douglas M.; Wyde, Philip R.; Wang, Nan; Newman, Patrick; Tseng, Chien-Te; Peters, C. J.; Makino, Shinji.

In: Vaccine, Vol. 26, No. 6, 06.02.2008, p. 797-808.

Research output: Contribution to journalArticle

Lokugamage, Kumari G. ; Yoshikawa-Iwata, Naoko ; Ito, Naoto ; Watts, Douglas M. ; Wyde, Philip R. ; Wang, Nan ; Newman, Patrick ; Tseng, Chien-Te ; Peters, C. J. ; Makino, Shinji. / Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. In: Vaccine. 2008 ; Vol. 26, No. 6. pp. 797-808.
@article{3ffdd8f455264d098b95266ca4664262,
title = "Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV",
abstract = "We tested the efficacy of coronavirus-like particles (VLPs) for protecting mice against severe acute respiratory syndrome coronavirus (SCoV) infection. Coexpression of SCoV S protein and E, M and N proteins of mouse hepatitis virus in 293T or CHO cells resulted in the efficient production of chimeric VLPs carrying SCoV S protein. Balb/c mice inoculated with a mixture of chimeric VLPs and alum twice at an interval of four weeks were protected from SCoV challenge, as indicated by the absence of infectious virus in the lungs. The same groups of mice had high levels of SCoV-specific neutralizing antibodies, while mice in the negative control groups, which were not immunized with chimeric VLPs, failed to manifest neutralizing antibodies, suggesting that SCoV-specific neutralizing antibodies are important for the suppression of viral replication within the lungs. Despite some differences in the cellular composition of inflammatory infiltrates, we did not observe any overt lung pathology in the chimeric-VLP-treated mice, when compared to the negative control mice. Our results show that chimeric VLP can be an effective vaccine strategy against SCoV infection.",
keywords = "Mouse, Neutralizing antibody, SARS coronavirus, Virus-like particles",
author = "Lokugamage, {Kumari G.} and Naoko Yoshikawa-Iwata and Naoto Ito and Watts, {Douglas M.} and Wyde, {Philip R.} and Nan Wang and Patrick Newman and Chien-Te Tseng and Peters, {C. J.} and Shinji Makino",
year = "2008",
month = "2",
day = "6",
doi = "10.1016/j.vaccine.2007.11.092",
language = "English (US)",
volume = "26",
pages = "797--808",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV

AU - Lokugamage, Kumari G.

AU - Yoshikawa-Iwata, Naoko

AU - Ito, Naoto

AU - Watts, Douglas M.

AU - Wyde, Philip R.

AU - Wang, Nan

AU - Newman, Patrick

AU - Tseng, Chien-Te

AU - Peters, C. J.

AU - Makino, Shinji

PY - 2008/2/6

Y1 - 2008/2/6

N2 - We tested the efficacy of coronavirus-like particles (VLPs) for protecting mice against severe acute respiratory syndrome coronavirus (SCoV) infection. Coexpression of SCoV S protein and E, M and N proteins of mouse hepatitis virus in 293T or CHO cells resulted in the efficient production of chimeric VLPs carrying SCoV S protein. Balb/c mice inoculated with a mixture of chimeric VLPs and alum twice at an interval of four weeks were protected from SCoV challenge, as indicated by the absence of infectious virus in the lungs. The same groups of mice had high levels of SCoV-specific neutralizing antibodies, while mice in the negative control groups, which were not immunized with chimeric VLPs, failed to manifest neutralizing antibodies, suggesting that SCoV-specific neutralizing antibodies are important for the suppression of viral replication within the lungs. Despite some differences in the cellular composition of inflammatory infiltrates, we did not observe any overt lung pathology in the chimeric-VLP-treated mice, when compared to the negative control mice. Our results show that chimeric VLP can be an effective vaccine strategy against SCoV infection.

AB - We tested the efficacy of coronavirus-like particles (VLPs) for protecting mice against severe acute respiratory syndrome coronavirus (SCoV) infection. Coexpression of SCoV S protein and E, M and N proteins of mouse hepatitis virus in 293T or CHO cells resulted in the efficient production of chimeric VLPs carrying SCoV S protein. Balb/c mice inoculated with a mixture of chimeric VLPs and alum twice at an interval of four weeks were protected from SCoV challenge, as indicated by the absence of infectious virus in the lungs. The same groups of mice had high levels of SCoV-specific neutralizing antibodies, while mice in the negative control groups, which were not immunized with chimeric VLPs, failed to manifest neutralizing antibodies, suggesting that SCoV-specific neutralizing antibodies are important for the suppression of viral replication within the lungs. Despite some differences in the cellular composition of inflammatory infiltrates, we did not observe any overt lung pathology in the chimeric-VLP-treated mice, when compared to the negative control mice. Our results show that chimeric VLP can be an effective vaccine strategy against SCoV infection.

KW - Mouse

KW - Neutralizing antibody

KW - SARS coronavirus

KW - Virus-like particles

UR - http://www.scopus.com/inward/record.url?scp=38349038213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349038213&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2007.11.092

DO - 10.1016/j.vaccine.2007.11.092

M3 - Article

VL - 26

SP - 797

EP - 808

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 6

ER -